Pandemic Pulse

The Gamaleya Center study in animals shows the intranasally delivered Sputnik V vaccine induces robust and durable immune response to coronavirus

The Gamaleya National Research Center of Epidemiology and Microbiology (Gamaleya Center) and the Russian Direct Investment Fund announce a publication in Emerging Microbes & Infections, a peer-reviewed medical journal, sharing the results of a study on intranasally delivered Sputnik V coronavirus vaccine. The study shows this type of the vaccine induces a strong and durable […]

Pandemic Pulse

Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax’ COVID-19 Vaccine in South Africa

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world’s largest vaccine manufacturer by volume, today announced a regulatory submission to the South African Health Products Regulatory Agency (SAHPRA) for emergency use authorization (EUA) of Novavax’ recombinant nanoparticle […]

Pandemic Pulse

A study published in The Lancet confirms the one-shot Sputnik Light vaccine has a high safety profile and induces a strong humoral and cellular immune response both in the seronegative and seropositive groups

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces a new publication by the Gamaleya Center in The Lancet, one of the world’s most respected medical journals, showing the one-shot Sputnik Light vaccine against coronavirus demonstrates a high safety profile and induces a strong humoral and cellular immune response. RDIF has sponsored the […]

Pandemic Pulse

Israel joins 100 other countries in accepting the Sputnik V vaccine

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces that Israeli authorities have granted approval for entry of individuals vaccinated with the Sputnik V vaccine. To date, a total of 101 countries have approved entry of those to have received the Sputnik V vaccine. Key requirements of the 101 countries which allow visits […]

Pandemic Pulse

Interim results of a pioneering combination study in Argentina with more than 1,000 participants confirm the one-shot Sputnik Light vaccine (the first component of the Sputnik V vaccine) is an effective universal booster for vaccines produced by Astrazeneca, Sinopharm, Moderna and Cansino inducing strong immune response and showing high safety profile. Combination of AstraZeneca and Sputnik Light vaccines showed high immunogenicity results.

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the interim results of the study in Argentina on heterogeneous regimens combining Sputnik Light (the first component of the Russian Sputnik V vaccine against coronavirus) and vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino. The study is co-sponsored by the Ministry of Health of Argentina […]

Pandemic Pulse

One-shot Sputnik Light vaccine (first component of the Sputnik V vaccine) demonstrates 70% efficacy against infection with the Delta variant during the first three months after vaccination, Gamaleya Center analysis shows

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Gamaleya National Research Center of Epidemiology and Microbiology today announced the results of an efficacy analysis of the one-shot Sputnik Light vaccine against infection from the Delta variant of coronavirus. Gamaleya Center has submitted an article analyzing efficacy of Sputnik Light vaccine against the […]

Pandemic Pulse

A clinical study of the combination of AstraZeneca and Sputnik Light vaccines in Azerbaijan shows strong neutralizing antibodies growth in the majority of participants

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), AstraZeneca and R-Pharm announce preliminary virus neutralizing activity results of combined use of the AstraZeneca vaccine (developed jointly with the University of Oxford) and the first component of the Sputnik V vaccine (Sputnik Light vaccine based on human adenovirus serotype 26) obtained during the clinical […]